BackRegenxbio Overview

Regenxbio Receivables

Track Regenxbio's receivables ($110M) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Receivables
$106.75M
396.85% YoYΔ $85.27M vs prior year quarter

Peer trimmed avg / median

Loading

Regenxbio Receivables History

Loading

Regenxbio vs. peers: Receivables Comparison

Loading

Regenxbio Receivables Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Regenxbio (RGNX) FAQ

As of the most recent data (June 2026), RGNX shows a receivables of $110M. That compares with $21M in the prior-year period — up 396.9% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, RGNX's receivables is now $110M (was $21M) — a 396.9% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether Regenxbio is outperforming or lagging.

Tracking RGNX's receivables over time shows whether Regenxbio is scaling, shrinking, or reshaping that part of the business. The current reading is $110M That compares with $21M in the prior-year period — up 396.9% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this receivables page, Stockcircle has Regenxbio's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect receivables (currently $110M) with ownership activity and broader fundamentals.

Regenxbio's receivables is $110M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.